The patent allows the company to commercially exploit proprietary carbon nanotube (CNT) technology and other nanostructures to develop point of care (POC) in-vitro diagnostics, including a design for the Omega-3 Cardiac panel.
Cardiac panel, which is currently in initial clinical studies, is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.
The compact size of the electronic and credit card-sized disposable test cartridge can be configured to run a various tests from range of patient samples.
